PPIs reduce the effectiveness of clopidogrel (Plavix)
Pharmamotion has now a new page containing updates on clopidogrel – PPI interactions. The latest edition of the monthly newsletter from the Medicines and Healthcare products Regulatory Agency has issued a drug safety advice on the interaction between the antiplatelet drug clopidogrel (Plavix) and PPIs. They conclude that available data supports a clinically significant interaction […]
FDA recommendations on clopidogrel (Plavix) because of decreased response and PPI interactions
Pharmamotion has now a new page containing updates on clopidogrel PPI interactions. The FDA issued today an early communication about an ongoing safety review of the antiplatelet agent clopidogrel bisulfate (Plavix). The backgroung to this is the recent evidence of: A decreased response to clopidogrel in some patients. Since clopidogrel is a prodrug, genetic polymorphisms […]